As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

GLP-1 drugs, originally for type 2 diabetes, are increasingly used for weight loss, but they can worsen eating disorders. Rapid weight loss from these drugs can reinforce harmful eating behaviors and ...

Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery ...

One in eight Americans is currently taking a GLP-1 to lose weight or treat a chronic condition.

Saha is senior vice president of government affairs for Premier Inc. McMullan is senior director of payment policy at Premier Inc. Today, more than 40% of adults over 60 are considered obese, fueling ...

Public and private payers are struggling to keep up with ballooning demand. This is a KFF Health News story. After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley ...

MENLO PARK, Calif., June 10, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark ...

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. 1,2 For ...

Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...

Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability. The partnership combines ...

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...